Novo Nordisk has announced a $2 billion licensing deal with Chinese pharmaceutical company United Laboratories International for a new weight-loss and diabetes drug. The agreement grants Novo Nordisk the rights to develop and commercialize the drug outside of China, further expanding its portfolio in the GLP-1 drug market.
Article continues after these messages…
While other outlets focus on getting quotes from politicians who don't even live in our congressional district, we're focused on providing the hard-hitting truths and facts without political spin. We don't lock our news behind a paywall, will you help us keep it that way? If you're tired of news sweetened with confirmation bias, consider becoming a monthly supporter. But if you're not, that's fine too—we're confident in our mission and will be here if you decide you're ready for the truth. Just $5/month helps fund our local reporting, live election night coverage, and more.
Become a paid supporter for reduced ad experience!
As part of the deal, Novo Nordisk will pay $200 million upfront, with an additional $1.8 billion in potential milestone payments. The drug candidate, known as UBT251, is a triple agonist targeting GLP-1, GIP, and glucagon receptors. In early Phase 1 trials, patients taking the highest dose of UBT251 experienced an average weight loss of 15.1%, significantly higher than the 1.5% recorded in the placebo group.
Novo Nordisk, which developed popular weight-loss and diabetes drugs like Ozempic and Wegovy, has been a dominant player in the GLP-1 drug sector. However, the company’s stock has faced pressure in recent months. Shares of Novo Nordisk fell 3% on Monday and are down 18% year-to-date, partly due to investor concerns over a disappointing trial of a next-generation obesity drug.
Meanwhile, United Laboratories International has seen its stock surge following the announcement. Shares in the Hong Kong-listed company jumped 6% on Monday and have risen 35% this year, reflecting investor optimism about its drug development pipeline and the lucrative licensing deal with Novo Nordisk.
The agreement underscores Novo Nordisk’s continued efforts to maintain its leadership in the rapidly expanding weight-loss and diabetes treatment market. With GLP-1 drugs gaining popularity worldwide, pharmaceutical companies are increasingly investing in next-generation treatments to meet growing demand.
Article by “BB” Boring, Hagerstown, MD
“With years of experience writing ‘bad news’, I’m pleased to announce I will be writing the important local news about which I’m truly passionate for my beloved local radio station and news outlet, Radio Free Hub City!“
Unlike traditional news media outlets, Radio Free Hub City believes in readers compensating article authors directly! You can support BB’s continuing work here at Radio Free Hub City by contributing to her Patreon.
All articles written by independent contributors to Radio Free Hub City remain the property of the original author, and published with permission. Radio Free Hub City is not responsible for the contents of independent contributors’ articles.
Discover more from Radio Free Hub City
Subscribe to get the latest posts sent to your email.